Carsgen Therapeutics Corporation
Biotechnology Company
Why pick this one
Carsgen Therapeutics develops CAR-T therapies across hematologic malignancies and solid tumors, with zevor-cel and satri-cel approved in China.
Best for
- CAR-T therapy research and development
- Hematologic malignancy cell therapy programs
- Solid tumor CAR-T programs
- Allogeneic CAR-T platform collaborations
- CAR-T technology or product licensing partnerships
- Commercial-scale CAR-T manufacturing partnerships
Look elsewhere if
- Seeking a general medical clinic or direct emergency cancer treatment provider
- Seeking services outside biopharmaceutical research, clinical development, manufacturing, or partnering
Specialties
- CAR T-cell therapies for hematologic malignancies
- CAR T-cell therapies for solid tumors
- CAR T-cell therapies for autoimmune diseases
- BCMA autologous CAR T-cell product development
- Claudin18.2 autologous CAR T-cell product development
- Allogeneic CAR T-cell platform development
- In vivo CAR-T platform development
Certifications
- China Drug Production License for CAR T
- In-house GMP-compliant manufacturing capabilities
What makes them different
- More than 10 self-developed CAR-T products with global rights
- Zevor-cel and satri-cel approved for marketing in China
- Vertically integrated manufacturing covering plasmids, lentiviral vectors, and CAR T-cell production
- Proprietary THANK-uCAR, CycloCAR, LADAR, and CARvivo platforms
- Manufacturing facilities in Shanghai, China and Durham, USA
- Response time
- Aiming for faster turnaround times for patients through vertically integrated production
Distilled from this business's own website.
Contact & Location
- Address
- 4022 Stirrup Creek Dr Ste 325, Durham, NC 27703-8971
- Phone
- 19848885701
- Website
- https://www.carsgen.com
Services
- Target discovery
- Antibody development
- Preclinical research
- Clinical development
- Commercial-scale CAR T-cell manufacturing
- Technology and product licensing partnerships